IGF Level in Breast Cancer Patients Treated With Metformin
The purpose of this study is to examine the impact of metformin as an adjuvant to chemotherapy on IGF levels in both progressing and non progressing cases of metastatic breast cancer in female patients.
Breast Cancer Female
DRUG: MetFORMIN 500 Mg Oral Tablet|DRUG: Chemotherapy
IGF-1 levels, IGF-1 levels were measured before and after treatment., 6 months.
Progression-free survival (PFS), The measurement values of IGF were divided into two groups, high and low, based on the cut off value. After a year of observation, researchers in both groups compared their progression-free survival (PFS)., 1 Year
One hundred and seven women with metastatic breast cancer (MBC) are randomly assigned to either a metformin (500 mg twice daily) or placebo (placebo) group during chemotherapy. All patients followed the standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI). Blood IGF-1 levels were measured at the start of treatment (baseline) and again six months later.